MPG.eBooks - Search Results

1

CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

2

CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

3

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

CADTH

Subjects: “...Drug Costs...”

Read Now

4

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

5

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

6

CADTH Canadian Drug Expert Committee recommendation: Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

7

CADTH Canadian Drug Expert Committee recommendation: Vedolizumab (Entyvio -- Takeda Canada Inc.) : indication : for the treatment of adult patients with moderately to severely acti...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

8

CADTH Canadian drug expert committee recommendation: Burosumab (Crysvita -- Kyowa Kirin Limited) : indication : treatment of x-linked hypophosphatemia

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

9

Masks for prevention of influenza transmission in acute and long-term care settings : a review of clinical effectiveness, cost-effectiveness and guidelines

by Marchand, Dave K., Argáez, Charlene
Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

10

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis

Published 2020

CADTH

Subjects: “...Cost-Benefit Analysis...”

Read Now

11

CADTH Canadian Drug Expert Committee recommendation: Dupilumab (Dupixent -- Sanofi-Aventis Canada Inc.) : indication: atopic dermatitis

Published 2020

CADTH

Subjects: “...Cost-Benefit Analysis...”

Read Now

12

Civil and Military Airworthiness: Recent Developments and Challenges

by Kourousis, Kyriakos I.
Published 2020

MDPI - Multidisciplinary Digital Publishing Institute

Subjects: “...cost-benefit analysis...”

Read Now

13

CADTH Canadian Drug Expert Committee recommendation: Belimumab (Benlysta subcutaneous [SC] -- GlaxoSmithKline Inc.) : indication: systemic lupus erythematosus (SLE)

Published 2020

CADTH

Subjects: “...Cost-Benefit Analysis...”

Read Now

14

CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

15

CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

16

Immune checkpoint inhibitors for classical Hodgkin lymphoma in brentuximab vedotin-naïve patients : a review of clinical effectiveness, cost-effectiveness, and guidelines

by Williams, D., Gray, Casey, Picheca, Lory
Published 2019

CADTH

Subjects: “...Cost-Benefit Analysis...”

Read Now

17

Nutritional Value of Pulses and Whole Grains

by Marinangeli, Christopher P. F.
Published 2022

MDPI - Multidisciplinary Digital Publishing Institute

Subjects: “...healthcare cost...”

Read Now

18

Neonatal Health Care

by Lee, Henry C.
Published 2021

MDPI - Multidisciplinary Digital Publishing Institute

Subjects: “...health care costs...”

Read Now

19

Biologics versus immunomodulators or antibiotics for the management of fistulizing Crohn's disease : a review of comparative clinical effectiveness and cost-effectiveness

by Young, Calvin, Campbell, Kaitryn
Published 2019

CADTH

Subjects: “...Cost-Benefit Analysis...”

Read Now

20

Biologics versus immunomodulators or antibiotics for the management of fistulizing Crohn's disease : a review of comparative clinical effectiveness and cost-effectiveness

by Young, Calvin, Campbell, Kaitryn
Published 2019

CADTH

Subjects: “...Cost-Benefit Analysis...”

Narrow Search